康宁杰瑞拿回增长主动权?来源|医药研究社港股医药牛市中,康宁杰瑞也是被新药带飞的典型了。日前,康宁杰瑞发布公告称,其产品JSKN003已获美国食品药品监督管理局(FDA)授予孤儿药资格认定(ODD),用于治疗胃癌及胃食管结合部癌(GC/GEJ)。据悉,ODD是FDA鼓励开发用于治疗在美国患病人数低于20万的疾病的创新药措施。JSKN003获得该认定将有利于其后续在美国获得研究及开发、注册与商业化等...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.